View allAll Photos Tagged Aranesp.;
In speaking with the nice guard outside today, he says Amgen is a laid-back place to work and the noise levels are typical for a warehouse. It is a large shipping warehouse for cancer treatment drugs. They recently expanded.
12000 Plantside Dr, Louisville, KY 40299
********
From Wikipedia - a little history:
The company has made at least five major corporate acquisitions.
Timeline
1980. William Bowes from Cetus Corporation recruits Winston Salser from UCLA to start Amgen with a scientific advisory board consisting of Normam Davidson, Leroy Hood, Arnold Berk, John Carbon, Robert Schimke, Arno Motulsky, Marvin H. Caruthers, and Dave Gibson.[7]
1989. Amgen received approval for the first recombinant human erythropoetin product, Epogen, for the treatment of anemia associated with chronic kidney failure. Epogen (also marketed by Johnson and Johnson under the tradename Procrit) would later be approved for anemia due to cancer chemotherapy, anemia due to treatment with certain HIV drugs, and for the reduction of the need for transfusions associated with surgery.[8]
1991. In February 1991, Amgen received FDA approval for Neupogen for the prevention of infections in patients whose immune systems are suppressed due to cancer chemotherapy.[9] A 2002 meta-analysis found that Neupogen treatment reduced the risk of febrile neutropenia by 38%, reduced the risk of documented infection by 49%, and reduced the risk of infection-related mortality by 40%.[10]
1998. In November 1998, Immunex, a future acquisition of Amgen, received approval for Enbrel (etanercept), the first rheumatoid arthritis drug targeting tumor necrosis factor alpha (TNF-alpha).[8] A 2006 assessment by the National Institute of Clinical Excellence of the United Kingdom concluded that etanercept and related rheumatoid arthritis drugs later introduced by competitors "are effective treatments compared with placebo for RA patients who are not well controlled by conventional DMARDs, improving control of symptoms, improving physical function, and slowing radiographic changes in joints."[11] A more recent study demonstrated that compared to traditional disease-modifying anti-rheumatic drugs, treatment with etanercept improved survival, reduced cardiovascular events and reduced the incidence of hematological cancers.[12]
2010. On June 6, 2010 Amgen received FDA approval for Prolia, a protein drug for the treatment of post-menopausal osteoporosis.[13] In clinical trials, Prolia reduced the rate of vertebral fractures by 61% and the risk of hip fractures by 40%.[14]
2010 In November 2010 the FDA approved Xgeva for the prevention of complications of bone metastases in patients with solid tumors.[15] The clinical trials primarily enrolled patients with breast or prostate cancer.
2012. Illegal marketing practices. The Los Angeles Times reported on December 18, 2012, that AMGEN pleaded guilty and agreed to pay $150 million in criminal penalty and $612 million to resolve 11 related whistleblower complaints. Federal prosecutors accused the company of pursuing profits while putting patients at risk.[16] Larry Husten, a contributor at Forbes.com elaborates on AMGEN's illegal marketing practices in this case, namely that the "government accused Amgen of marketing Aranesp for indications not approved by the FDA and other illegal marketing practices".[17] One of the drugs mentioned in the lawsuit had sales of $492 million in the third quarter of 2012, down 17% from the same quarter the previous year due to "reimbursement problems and label changes".[18]
2012. Amgen paid $762 million after pleading guilty to criminal charges of improper promotion and sale of misbranded drugs.[19]
2013. Lawmakers inserted text into the fiscal cliff bill that will allow the drugmaker to sell a class of drugs that includes Sensipar without government controls for an additional two years. The New York Times estimated that the paragraph in the fiscal cliff bill will cost taxpayers an estimated $500 million[20] but other assessments concluded that the change would protect seniors in rural areas and reduce overall Medicare spending.[21][22]
2015. In September the company announced it would acquire Dezima Pharma for more than $1.55 billion.[23] The same day the company announced a collaboration with Xencor on 6 early stage immuno-oncology and inflammation programmes. As part of the deal Amgen will pay $45 million upfront, with the deal being worth up to another $1.7 billion.[24][25]
2016. In September, the company announced it would purchase the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound (BI 836909, now AMG 420) for use in the treatment of multiple myeloma.[26]
*******************
From the Wall Street Journal 5/29/21: A pathbreaking pill for lung cancer from Amgen Inc. was approved by the U.S. Food and Drug Administration, adding a new potential blockbuster to the biotech giant’s aging stable of drugs.
The drug, called Lumakras, was approved Friday to treat a portion of lung cancer patients with a particular genetic mutation who have already tried other therapies.
The mutation, known as KRAS, is among the most common found in cancers, but researchers struggled for so many years to find a medicine that can treat it that the mutation came to be considered “undruggable.”
Amgen Wins Approval for Pathbreaking Lung Cancer Drug (By Joseph Walker
Updated May 28, 2021 3:42 pm ET): www.wsj.com/articles/amgen-wins-approval-for-pathbreaking...
***********
It is ironic that stem-cell treatment is used in other Nations successfully in combating cancer, yet not in the USA.
They just make you worse.
I don't know about any of you, but many of my friends and I have health problems where the prescribed medications' side effects are just about as terrible as the illness itself, if not worse. And let's add of the fact that most of us don't have health insurance and these medications are hundreds of dollars a month.
To quote a friend of mine, "Don't want to live with them, won't live long without them."
Aranesp - One of my weekly injections.
This med increases my haemoglobin which in turn increases the oxygen un my blood.
I have been starving for Oxygen so one of my specialists increased my weekly Aranesp to 100 to help me create more haemoglobin.
Recent pharma happenings:
Alnylam Pharmaceuticals Releases Phase III ILLUMINATE-A Trial Results Testing #Lumasiran for #PrimaryHyperoxaluria Type 1.;
AstraZeneca's #BloodCancer Drug #Calquence Might be the New Weapon to Fight #COVID19.;
Astellas Pharma US Presents Phase III #DOLOMITES Trial Results, Shows Non-inferiority of its #Roxadustat to Amgen's #Aranesp.;
Evotec Partners with Advanced BioScience Laboratories, Plans to Design Bradly Neutralising #Antibody Against #HIV.
For more details visit: lnkd.in/grNuzkW
#pharmaceutical #news #healthcarenews #lifesciences #biotechnology #pharmanews #coronavirusupdates #coronavirus #market #marketresearch
Aranesp - darbepoetin alfa.
Once a week shot to increase my haemoglobin to increase my oxygen.
The cost is so much that our local hospital issues this med to me in a cold bag at no charge instead of my having to purchase the Rx from a pharmacy.
Reminder stickers and data for:
Aranesp - darbepoetin alfa.
Once a week shot to increase my haemoglobin to increase my oxygen.
Renal Clinic visit. Many boxes of pre-filled Aranesp needles which are prescribed to increase my oxygen. The hospital is terrific in that they provide these very expensive doses to me at no cost.